Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 287-294

  Mischo, Axel ^a   Bubel, Nina ^b   Cebon, Jonathan S ^c   Samaras, Panagiotis ^a   Petrausch, Ulf ^a   Stenner Liewen, Frank ^a   Schaefer, Niklaus G ^a   Kubuschok, Boris ^b   Renner, Christoph ^a   Wadle, Andreas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Antibody; IgG subclass; ISCOMATRIX; NY ESO 1; Recombinant antigen expression on yeast surface

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN LAGE 1A; CANCER TESTIS ANTIGEN LAGE 1B; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOLOGICAL ADJUVANT; ISCOMATRIX; NY ESO 1 ANTIGEN; RECOMBINANT NY ESO 1 ANTIGEN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CROSS REACTION; DRUG DOSE INCREASE; HUMAN; HUMORAL IMMUNITY; MELANOMA; PRIORITY JOURNAL; SEROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CHOLESTEROL; CROSS-PRIMING; DRUG COMBINATIONS; EPITOPES; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MEMBRANE PROTEINS; NEOPLASMS; PHOSPHOLIPIDS; RECOMBINANT PROTEINS; SAPONINS; T-LYMPHOCYTES; YEASTS;

EID: 79956044152     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1032     Document Type: Article

References (35)

1. Baxevanis CN, Perez SA and Papamichail M: Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 58: 317-324, 2009.
2. Fiszer D and Kurpisz M: Major histocompatibility complex expression on human, male germ cells: a review. Am J Reprod Immunol 40: 172-176, 1998. (Pubitemid 28380118)
3. Scanlan MJ, Simpson AJ and Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4: 1, 2004.
4. Chen YT, Scanlan MJ, Sahin U, et al: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94: 1914-1918, 1997.
5. Gnjatic S, Nishikawa H, Jungbluth AA, et al: NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 95: 1-30, 2006. (Pubitemid 44088423)
6. Mischo A, Wadle A, Watzig K, et al: Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun 3: 5, 2003.
7. Boder ET and Wittrup KD: Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol 328: 430-444, 2000.
8. Boder ET and Wittrup KD: Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15: 553-557, 1997. (Pubitemid 27251573)
9. Wadle A, Mischo A, Imig J, et al: Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library. Int J Cancer 117: 104-113, 2005. (Pubitemid 41262764)
10. Wadle A, Kubuschok B, Imig J, et al: Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 119: 117-125, 2006.
11. Mischo A, Kubuschok B, Ertan K, et al: Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 118: 696-703, 2006. (Pubitemid 43076020)
12. Kim MS, Choi HY, Choi YS, Kim J and Kim YS: Optimized serological isolation of lung-cancer-associated antigens from a yeast surface-expressed cDNA library. J Microbiol Biotechnol 17: 993-1001, 2007. (Pubitemid 47162064)
13. Disis ML, Calenoff E, McLaughlin G, et al: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20, 1994. (Pubitemid 24042079)
14. Jager E, Chen YT, Drijfhout JW, et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270, 1998. (Pubitemid 28060443)
15. Dhodapkar KM, Krasovsky J, Williamson B and Dhodapkar MV: Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195: 125-133, 2002. (Pubitemid 34074502)
16. Valmori D, Souleimanian NE, Tosello V, et al: Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104: 8947-8952, 2007. (Pubitemid 47175417)
17. Davis ID, Chen W, Jackson H, et al: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101: 10697-10702, 2004. (Pubitemid 38955805)
18. Sahin U, Tureci O, Schmitt H, et al: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813, 1995. (Pubitemid 26014201)
19. Sjolander A, Ahlborg N, Stahl S and Andersson R: Characterization of immune responses to experimental polyvalent subunit vaccines assembled in iscoms. Mol Immunol 35: 159-166, 1998. (Pubitemid 28319921)
20. + tumors. Clin Cancer Res 10: 2879-2890, 2004. (Pubitemid 38509168)
21. Jager E, Stockert E, Zidianakis Z, et al: Humoral immune responses of cancer patients against cancer-testis antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84: 506-510, 1999.
22. Jager E, Nagata Y, Gnjatic S, et al: Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 97: 4760-4765, 2000. (Pubitemid 30238631)
23. Stockert E, Jager E, Chen YT, et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354, 1998. (Pubitemid 28189124)
24. Valmori D, Souleimanian NE, Hesdorffer CS, Ritter G, Old LJ and Ayyoub M: Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin Immunol 117: 24-30, 2005. (Pubitemid 41725466)
25. Papadea C and Check IJ: Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Crit Rev Clin Lab Sci 27: 27-58, 1989. (Pubitemid 19138489)
26. Regnault A, Lankar D, Lacabanne V, et al: Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 189: 371-380, 1999. (Pubitemid 29063258)
27. van de Winkel JG and Capel PJ: Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 14: 215-221, 1993.
28. Houghton AN and Scheinberg DA: Monoclonal antibody therapies-a 'constant' threat to cancer. Nat Med 6: 373-374, 2000.
29. Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H and Magnusson CG: Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res 62: 1364-1369, 2002. (Pubitemid 34407793)
30. + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 101: 9363-9368, 2004. (Pubitemid 38812881)
31. + memory T cells. Immunol Rev 211: 146-153, 2006. (Pubitemid 43882968)
32. + T-helper and a T-killer cell. Nature 393: 474-478, 1998.
33. + T cell memory. Science 297: 2060-2063, 2002.
34. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100: 8862-8867, 2003.
35. Nagata Y, Ono S, Matsuo M, et al: Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 99: 10629-10634, 2002.